{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T05:17:17Z","timestamp":1788239837815,"version":"build-2803163510"},"reference-count":5,"publisher":"Jaypee Brothers Medical Publishing","issue":"8","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.59556\/japi.74.1565","type":"journal-article","created":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T04:31:59Z","timestamp":1788237119000},"page":"92-92","source":"Crossref","is-referenced-by-count":0,"title":["Reappraisal of Comparison of the Efficacy and Safety of Biosimilar Adalimumab with Innovator Adalimumab in Ankylosing Spondylitis"],"prefix":"10.59556","volume":"74","author":[{"given":"Nitin Chintaman","family":"Gawari","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tanvi","family":"Naik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sujata Prakash","family":"Shingare","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasir","family":"Hassan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2914","reference":[{"issue":"(9):","key":"key20260901043113_B1","doi-asserted-by":"crossref","first-page":"e21\u2013","DOI":"10.59556\/japi.73.1117","article-title":"Comparison of the efficacy and safety of biosimilar adalimumab injection with innovator adalimumab in subjects with active ankylosing spondylitis.","volume":"73","author":"Chandrashekara","year":"2025;","journal-title":"J Assoc Physicians India"},{"issue":"(8):","key":"key20260901043113_B2","first-page":"834\u2013","article-title":"CONSORT 2010 statement: updated guidelines for reporting parallel group randomised trials.","volume":"63","author":"Schulz","year":"2010;","journal-title":"J ClinEpidemiol"},{"issue":"(24):","key":"key20260901043113_B3","doi-asserted-by":"crossref","first-page":"2594\u2013","DOI":"10.1001\/jama.2012.87802","article-title":"Reporting of noninferiority and equivalence randomized trials: extension of the CONSORT 2010 statement.","volume":"308","author":"Piaggio","year":"2012;","journal-title":"JAMA"},{"key":"key20260901043113_B4","doi-asserted-by":"crossref","DOI":"10.17226\/27746","volume-title":"Evidence Review of the Adverse Effects of COVID-19 Vaccination and Intramuscular Vaccine Administration.","author":"Bass","year":"2024."},{"issue":"(1):","key":"key20260901043113_B5","doi-asserted-by":"crossref","first-page":"e35\u2013","DOI":"10.1016\/S2665-9913(19)30013-X","article-title":"IBI303, a biosimilar to adalimumab, for the treatment of patients with ankylosing spondylitis in China: a randomised, double-blind, phase 3 equivalence trial.","volume":"1","author":"Xu","year":"2019;","journal-title":"Lancet Rheumatol"}],"container-title":["Journal of The Association of Physicians of India"],"original-title":[],"language":"en","deposited":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T04:32:03Z","timestamp":1788237123000},"score":1,"resource":{"primary":{"URL":"https:\/\/japi.org\/article\/japi-74-8-92"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":5,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["10.59556\/japi.74.1565"],"URL":"https:\/\/doi.org\/10.59556\/japi.74.1565","relation":{},"ISSN":["0004-5772"],"issn-type":[{"value":"0004-5772","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]}}}